Costs associated with the management of overactive bladder and related comorbidities.
OBJECTIVE
To evaluate the clinical and economic impact of overactive bladder (OAB) on the management of related comorbidities in a managed care population.


METHODS
Retrospective analysis of a claims database.


METHODS
A large managed care organization in the United States.


METHODS
A total of 11,556 patients with OAB who were aged 18 years or older and 11,556 control subjects without OAB who were matched on propensity score.


RESULTS
Patients and controls were identified from July 1-December 31, 2001, and followed for 360 days. The propensity score for matching controls was estimated based on patient demographics and diagnosis of important clinical conditions during a 180-day preindex period. Medical claims were examined for any diagnosis of the studied comorbidities. Submitted medical charges for claims with a primary or secondary diagnosis of the studied comorbidities were analyzed. Prevalence and medical charges for depression, skin infections, and vulvovaginitis were compared between patients with OAB and control subjects by using chi2 and t tests. Prevalence and medical charges for falls and fractures, urinary tract infections (UTIs), and any comorbidity were compared by using logistic regression and general linear modeling, to adjust for additional confounders not included in the matching process. Prevalence of all comorbid conditions was significantly higher (p<0.0001) for patients with OAB than for control subjects: falls and fractures, 25.3% versus 16.1%; depression, 10.5% versus 4.9%; UTIs, 28.0% versus 8.4%; skin infections, 3.9% versus 2.3%; vulvovaginitis, 4.7% versus 1.8%; any of these comorbidities, 52.1% versus 27.9%. Mean annual medical charges were significantly higher for patients than for controls for all comorbidities: falls and fractures, $934 versus $598 (p<0.0001); depression, $93 versus $23 (p<0.0001); UTIs, $603 versus $176 (p<0.0001); skin infections, $67 versus $10 (p=0.002); vulvovaginitis, $11 versus $3 (p<0.0001); any comorbidity, $1689 versus $829 (p<0.0001).


CONCLUSIONS
This study quantifies the increased prevalence of and additional medical costs associated with related comorbidities in patients with OAB, emphasizing that the economic and clinical impact of OAB extends beyond the disease itself. Thus, management of patients with OAB should be of greater focus with both clinicians and health care payers.
Pharmacoeconomics and Health Outcomes Research, Prescription Solutions, Costa Mesa, California 92626, USA.
Theodore
T
Darkow
Christina L
CL
Fontes
Todd E
TE
Williamson
D000368:Aged; D015331:Cohort Studies; D015897:Comorbidity; D005260:Female; D017048:Health Care Costs; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D014549:Urinary Incontinence / Q000191:economics* / Q000453:epidemiology / Q000628:therapy*